Overview Dividends

(PFE) Pfizer - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7170811035

Vaccines, Antivirals, Oncology, Immunology, Sterile-Injectables

PFE EPS (Earnings per Share)

EPS Growth (3Y CAGR): -9.36%
EPS Trend (3Y Correlation): 5.9%

PFE Revenue

Revenue Growth (3Y CAGR): -12.82%
Revenue Trend (3Y Correlation): -26.4%

Risk via 10d forecast
Volatility	20.8%
Value at Risk 5%th	44.4%

Reward
Sharpe Ratio	0.06
Alpha Jensen	-8.08

Character
Hurst Exponent	0.431
Beta	0.425

Drawdowns 3y
Max DD	55.31%
Mean DD	39.21%

Description: PFE Pfizer September 25, 2025

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells a broad portfolio of biopharmaceutical products worldwide, spanning small-molecule drugs, biologics, vaccines, and biosimilars across multiple therapeutic areas.

Key therapeutic segments include cardiovascular and migraine treatments (e.g., Eliquis, Nurtec ODT), infectious-disease vaccines (Prevnar, Abrysvo), COVID-19 prevention and therapy (Comirnaty, Paxlovid), and specialty medicines for chronic immune, inflammatory, hematologic, and endocrine disorders (Xeljanz, Enbrel, Oxbryta, Ibrance, etc.). The company also operates a contract-manufacturing business and serves a diverse customer base that includes wholesalers, hospitals, pharmacies, and government agencies.

Recent performance metrics (as of Q2 2024) show a revenue run-rate of roughly $14 billion, driven largely by sustained demand for COVID-19 products and a 7 % YoY growth in the vaccine segment, while the biosimilar portfolio contributed a 12 % increase in margin expansion. A primary sector driver is the aging global population, which underpins rising demand for chronic-disease therapies, and a secondary driver is the ongoing shift toward mRNA and antiviral platforms, where Pfizer’s partnership with BioNTech positions it to capture a growing market share.

For a deeper, data-rich analysis of Pfizer’s valuation dynamics and scenario modeling, you may find additional insights on ValueRay helpful.

PFE Stock Overview

Market Cap in USD	138,902m
Sub-Industry	Pharmaceuticals
IPO / Inception	2012-08-13
Return 12m vs S&P 500	-9.71%
Analyst Rating	3.56 of 5

PFE Dividends

Dividend Yield	6.74%
Yield on Cost 5y	5.99%
Yield CAGR 5y	3.89%
Payout Consistency	97.8%
Payout Ratio	58.7%

PFE Growth Ratios

CAGR	-14.64%
CAGR/Max DD Calmar Ratio	-0.26
CAGR/Mean DD Pain Ratio	-0.37
Current Volume	139570.3k
Average Volume	50152.4k

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (9.82b TTM) > 0 and > 6% of Revenue (6% = 3.77b TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA 1.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 16.45% (prev 0.02%; Δ 16.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 13.08b > Net Income 9.82b (YES >=105%, WARN >=100%)

Net Debt (60.37b) to EBITDA (21.17b) ratio: 2.85 <= 3.0 (WARN <= 3.5)

Current Ratio 1.28 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (5.71b) change vs 12m ago 0.16% (target <= -2.0% for YES)

Gross Margin 71.19% (prev 58.73%; Δ 12.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 29.32% (prev 27.54%; Δ 1.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.36 (EBITDA TTM 21.17b / Interest Expense TTM 2.70b) >= 6 (WARN >= 3)

Altman Z'' 3.70

(A) 0.05 = (Total Current Assets 46.92b - Total Current Liabilities 36.60b) / Total Assets 208.73b

(B) 0.58 = Retained Earnings (Balance) 121.15b / Total Assets 208.73b

(D) 0.98 = Book Value of Equity 113.56b / Total Liabilities 115.64b

Total Rating: 3.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 63.65

1. Piotroski 6.0pt = 1.0

2. FCF Yield 5.59% = 2.79

3. FCF Margin 16.53% = 4.13

4. Debt/Equity 0.66 = 2.28

5. Debt/Ebitda 2.85 = -1.55

6. ROIC - WACC (= 4.61)% = 5.76

7. RoE 10.91% = 0.91

8. Rev. Trend -26.42% = -1.98

9. EPS Trend 5.91% = 0.30

What is the price of PFE shares?

As of November 12, 2025, the stock is trading at USD 25.51 with a total of 139,570,300 shares traded.
Over the past week, the price has changed by +6.83%, over one month by +4.97%, over three months by +5.61% and over the past year by +4.25%.

Is Pfizer a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Pfizer is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 63.65 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PFE is around 23.14 USD . This means that PFE is currently overvalued and has a potential downside of -9.29%.

Is PFE a buy, sell or hold?

Pfizer has received a consensus analysts rating of 3.56. Therefor, it is recommend to hold PFE.

Strong Buy: 7
Buy: 2
Hold: 15
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the PFE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	28.7	12.5%
Analysts Target Price	28.7	12.5%
ValueRay Target Price	25.1	-1.5%

PFE Fundamental Data Overview November 09, 2025

Market Cap USD = 138.90b (138.90b USD * 1.0 USD.USD)
P/E Trailing = 14.2035
P/E Forward = 8.673
P/S = 2.2123
P/B = 1.7359
P/EG = 3.7725
Beta = 0.425
Revenue TTM = 62.78b USD
EBIT TTM = 14.47b USD
EBITDA TTM = 21.17b USD
Long Term Debt = 56.70b USD (from longTermDebt, last fiscal year)
Short Term Debt = 4.30b USD (from shortTermDebt, last quarter)
Debt = 61.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.37b USD (from netDebt column, last quarter)
Enterprise Value = 185.63b USD (138.90b + Debt 61.71b - CCE 14.98b)
Interest Coverage Ratio = 5.36 (Ebit TTM 14.47b / Interest Expense TTM 2.70b)
FCF Yield = 5.59% (FCF TTM 10.38b / Enterprise Value 185.63b)
FCF Margin = 16.53% (FCF TTM 10.38b / Revenue TTM 62.78b)
Net Margin = 15.64% (Net Income TTM 9.82b / Revenue TTM 62.78b)
Gross Margin = 71.19% ((Revenue TTM 62.78b - Cost of Revenue TTM 18.09b) / Revenue TTM)
Gross Margin QoQ = 74.95% (prev 64.29%)
Tobins Q-Ratio = 0.89 (Enterprise Value 185.63b / Total Assets 208.73b)
Interest Expense / Debt = 1.06% (Interest Expense 652.0m / Debt 61.71b)
Taxrate = -6.48% (negative due to tax credits) (-216.0m / 3.33b)
NOPAT = 15.41b (EBIT 14.47b * (1 - -6.48%)) [negative tax rate / tax credits]
Current Ratio = 1.28 (Total Current Assets 46.92b / Total Current Liabilities 36.60b)
Debt / Equity = 0.66 (Debt 61.71b / totalStockholderEquity, last quarter 92.80b)
Debt / EBITDA = 2.85 (Net Debt 60.37b / EBITDA 21.17b)
Debt / FCF = 5.82 (Net Debt 60.37b / FCF TTM 10.38b)
Total Stockholder Equity = 90.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.71% (Net Income 9.82b / Total Assets 208.73b)
RoE = 10.91% (Net Income TTM 9.82b / Total Stockholder Equity 90.01b)
RoCE = 9.87% (EBIT 14.47b / Capital Employed (Equity 90.01b + L.T.Debt 56.70b))
RoIC = 10.20% (NOPAT 15.41b / Invested Capital 151.03b)
WACC = 5.59% (E(138.90b)/V(200.61b) * Re(7.58%) + D(61.71b)/V(200.61b) * Rd(1.06%) * (1-Tc(-0.06)))
Discount Rate = 7.58% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.59%
[DCF Debug] Terminal Value 74.43% ; FCFE base≈9.52b ; Y1≈7.55b ; Y5≈5.05b
Fair Price DCF = 16.53 (DCF Value 93.99b / Shares Outstanding 5.69b; 5y FCF grow -24.64% → 3.0% )
EPS Correlation: 5.91 | EPS CAGR: -9.36% | SUE: 2.02 | # QB: 8
Revenue Correlation: -26.42 | Revenue CAGR: -12.82% | SUE: 0.08 | # QB: 0

Additional Sources for PFE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle